Biotechnology

Lunai Bioworks announced a 1‑for‑8 reverse stock split effective May 22 2026, reducing shares from ~36.3 million to ~4.5 million. The split aims to lift the share price above Nasdaq’s $1.00 minimum, a

Ichnos Glenmark Innovation announced ISB 2301, a first-in-class multispecific antibody targeting solid tumors by activating T and NK cells. The candidate targets three tumor-associated antigens and is

SPARC's licensing partner Ocuvex Therapeutics received a Complete Response Letter from the US FDA for its PDP-716 New Drug Application. The FDA's CRL was issued solely due to inspection findings at th

Ministry of Tribal Affairs organized workshop on India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease. Ministry provided Rs 3.75 crore financial assistance for the BIRSA 101 gene